- Home
- ATYR vs JHI Comparison
ATYR vs JHI Comparison
Compare ATYR & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATYR | JHI |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 123.7M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATYR | JHI |
|---|---|---|
| Price | $0.78 | $13.72 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 29.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | ★ $190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | N/A |
| P/E Ratio | ★ N/A | $12.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $11.63 |
| 52 Week High | $7.29 | $13.40 |
Technical Indicators
Market Signals| Indicator | ATYR | JHI |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 39.32 |
| Support Level | $0.70 | $13.93 |
| Resistance Level | $0.83 | $14.21 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 57.87 | 18.06 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.